The Pharmacopoeia Commission publicizes draft national standards for 14 varieties of chemical drugs

In October, the Pharmacopoeia Commission announced draft national standards for 14 varieties of chemical drugs: fluvastatin sodium capsules, desloratadine disodium citrate, desloratadine disodium citrate tablets, desloratadine Disodium citrate capsules, meta-hydroxylamine bitartrate, fluvastatin sodium, mercaptopurine tablets, mercaptopurine, benproperine phosphate capsules, benproperine phosphate tablets, salbutamol sulfate orally disintegrating tablets, salbutamol sulfate injection, sulfuric acid The publicity period of salbutamol tablets and salbutamol sulfate is three months from the date of release

1.

Our committee plans to revise the national drug standard for fluvastatin sodium capsules.

Contact: Zhou Yi, Guo Wei

Phone: 010-67079556, 010-67079558

Email: zhouyi@chp.

Recipient: Office of the National Pharmacopoeia Commission

Address: Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 13, 2021

Attachment: The second public announcement draft of the revised draft of the national drug standard for fluvastatin sodium capsules.

2.

Our committee plans to formulate a national drug standard for desloratadine disodium citrate (formerly known as desloratadine citrate).

Failure to respond to comments at the expiration of the publicity period shall be deemed to have no objection to the draft publicity standard

Contact: Cheng Qilei and Guo Wei

Phone: 010-67079557010-67079558

Email: chengqilei@chp.

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 13, 2021

Attachment: desloratadine disodium citrate-publication standard.

3.

Our committee plans to formulate a national drug standard for desloratadine disodium citrate tablets (previously used name: desloratadine citrate tablets).

Failure to respond to comments at the expiration of the publicity period shall be deemed to have no objection to the draft publicity standard

Contact: Cheng Qilei and Guo Wei

Phone: 010-67079557010-67079558

Email: chengqilei@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 13, 2021

Attachment: desloratadine disodium citrate tablets-publication standard.
pdf

4.
Deloratadine Disodium Citrate Capsules

Our committee plans to formulate a national drug standard for desloratadine disodium citrate capsules (formerly known as desloratadine citrate capsules).
To ensure the scientificity, rationality and applicability of the standard, it will now be formulated Desloratadine Disodium Citrate Capsules National Drug Standard Publicity Solicits opinions from all walks of life (see attachment for details)
.
The publicity period is three months
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Failure to respond to comments at the expiration of the publicity period shall be deemed to have no objection to the draft publicity standard
.

Contact: Cheng Qilei and Guo Wei

Phone: 010-67079557010-67079558

Email: chengqilei@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 13, 2021

Attachment: Deloratadine Disodium Citrate Capsules-Publication Standard.
pdf

5.
Meta-hydroxylamine bitartrate

Picture Our committee plans to revise the national drug standard for meta-hydroxylamine bitartrate (Chinese Pharmacopoeia 2020 edition two).
In order to ensure the scientificity, rationality and applicability of the standard, the proposed revision of the meta-hydroxylamine bitartrate drug standard is now publicized to solicit opinions from all walks of life (See the attachment for details)
.
The publicity period is three months from the date of publication
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Contact: Zhou Yi, Guo Wei

Phone: 010-67079556, 010-67079558

Email: zhouyi@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 13, 2021

Attachment: Announcement Draft of the Revised National Drug Standard of 0 Meta-Hydroxyamine Bitartrate 20211011.
pdf

6.
Fluvastatin sodium

Our committee plans to formulate a national drug standard for fluvastatin sodium.
In order to ensure the scientificity, rationality and applicability of the standard, the proposed national drug standard for fluvastatin sodium is now publicized to solicit opinions from all walks of life (see attachment for details)
.
The publicity period is three months
.
Relevant units are requested to study and verify carefully.
If you have any objections, please submit your feedback in time, with relevant instructions, experimental data and contact information
.
The letter must be stamped with the official seal, and the receiving unit is the "Office of the National Pharmacopoeia Commission".
At the same time, the scanned copy of the official letter will be sent to the designated mailbox
.
Failure to respond to comments at the expiration of the publicity period shall be deemed to have no objection to the draft publicity standard
.

Contact: Zhou Yi, Guo Wei

Phone: 010-67079556, 010-67079558

Email: zhouyi@chp.
org.
cn

Recipient: Office of the National Pharmacopoeia Commission

Address: Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 13, 2021

Attachment: The second public announcement draft of fluvastatin sodium national drug standard.
pdf

7.
Mercaptopurine tablets

Our committee intends to revise the pharmacopoeial standards of mercaptopurine tablets.
To ensure the scientificity, rationality and applicability of the standards, the proposed pharmacopoeial standards for mercaptopurine tablets are now publicly available to solicit opinions from all walks of life (see appendix for details)
.
The publicity period is 3 months from the date of publication
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Contact: Yue Zhihua, Guo Wei

Phone: 010-67079576, 010-67079558

Email: yuezhihua@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 11, 2021

Attachment: 0 Mercaptopurine Tablets-Pharmacopoeia Revised Public Notice Draft 202109.
pdf

8.
Mercaptopurine

The Commission intends to revise the pharmacopoeial standards of mercaptopurine.
To ensure the scientificity, rationality and applicability of the standards, the proposed pharmacopoeial standards for mercaptopurine are now publicly available to solicit opinions from all walks of life (see appendix for details)
.
The publicity period is 3 months from the date of publication
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Contact: Yue Zhihua, Guo Wei

Phone: 010-67079576, 010-67079558

Email: yuezhihua@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 11, 2021

Attachment: 0 Mercaptopurine-Pharmacopoeia Revised Public Notice Draft 202109.
pdf

9.
Benproperine phosphate capsules

Our committee plans to revise the national drug standard for benproperine phosphate capsules.
To ensure the scientificity, rationality and applicability of the standard, the proposed revision of the national drug standard for benproperine phosphate capsules is now soliciting opinions from all walks of life (see attachment for details) )
.
The publicity period is one month from the date of publication
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Contact: Wang Zhijun; Guo Wei

Phone: 010-67079559; 010-67079558

Email: wangzhijun@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 09, 2021

Attachment: Benproperine Phosphate Capsules-Publication Draft (Second Time).
pdf

10.
Benproperine phosphate tablets

Our committee intends to revise the national drug standard for benproperine phosphate tablets.
To ensure the scientificity, rationality and applicability of the standard, the proposed revision of the national drug standard for benproperine phosphate tablets is now soliciting opinions from all walks of life (see appendix for details) )
.
The publicity period is one month from the date of publication
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Contact: Wang Zhijun; Guo Wei

Phone: 010-67079559; 010-67079558

Email: wangzhijun@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 09, 2021

Attachment: Benproperine Phosphate Tablets-Publication Draft (Second Time).
pdf

11.
Salbutamol sulfate orally disintegrating tablets

Our committee intends to revise the national drug standard for salbutamol sulfate orally disintegrating tablets.
To ensure the scientificity, rationality and applicability of the standard, the proposed revision of the national drug standard for salbutamol sulfate orally disintegrating tablets is now publicly solicited for opinions from all walks of life (see attachment for details)
.
The publicity period is three months from the date of publication
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Contact: Wang Zhijun; Guo Wei

Phone: 010-67079559; 010-67079558

Email: wangzhijun@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 09, 2021

Attachment: Salbutamol Sulfate Orally Disintegrating Tablets-Publication Draft.
pdf

12.
Salbutamol Sulfate Injection

Our committee intends to revise the national drug standard for salbutamol sulfate injection.
To ensure the scientificity, rationality and applicability of the standard, the proposed revision of the national drug standard for salbutamol sulfate injection is now publicly solicited for opinions from all walks of life (see attachment for details)
.
The publicity period is three months from the date of publication
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Contact: Wang Zhijun; Guo Wei

Phone: 010-67079559; 010-67079558

Email: wangzhijun@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 09, 2021

Attachment: Salbutamol Sulfate Injection-Publication Draft.
pdf

13.
Salbutamol Sulfate Tablets

Our committee plans to revise the national drug standard for salbutamol sulfate tablets.
To ensure the scientificity, rationality and applicability of the standard, the proposed revision of the national drug standard for salbutamol sulfate tablets is now publicly solicited for comments from all sectors of the society (see attachment for details)
.
The publicity period is three months from the date of publication
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Contact: Wang Zhijun; Guo Wei

Phone: 010-67079559; 010-67079558

Email: wangzhijun@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 09, 2021

Attachment: Salbutamol Sulfate Tablets-Publication Draft.
pdf

14.
Salbutamol sulfate

Our committee intends to revise the national drug standard of salbutamol sulfate.
To ensure the scientificity, rationality and applicability of the standard, the proposed revision of the national drug standard for salbutamol sulfate is now publicly solicited for opinions from all walks of life (see attachment for details)
.
The publicity period is three months from the date of publication
.
Please carefully research and verify.
If you have any objections, please submit feedback in a timely manner, with relevant instructions, experimental data and contact information
.
Letters from relevant units must be stamped with official seals, personal letters must be signed by themselves, and the electronic version must be sent to the designated mailbox
.

Contact: Wang Zhijun; Guo Wei

Phone: 010-67079559; 010-67079558

Email: wangzhijun@chp.
org.
cn

Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua South Lane, Dongcheng District, Beijing

Post Code: 100061

National Pharmacopoeia Committee

October 09, 2021

Attachment: Salbutamol Sulfate-Publication Draft.
pdf